ECSP23002960A - Fusiones heterodiméricas de relaxina y usos de las mismas - Google Patents

Fusiones heterodiméricas de relaxina y usos de las mismas

Info

Publication number
ECSP23002960A
ECSP23002960A ECSENADI20232960A ECDI202302960A ECSP23002960A EC SP23002960 A ECSP23002960 A EC SP23002960A EC SENADI20232960 A ECSENADI20232960 A EC SENADI20232960A EC DI202302960 A ECDI202302960 A EC DI202302960A EC SP23002960 A ECSP23002960 A EC SP23002960A
Authority
EC
Ecuador
Prior art keywords
relaxin
treatment
fusion polypeptides
heterodimer fusion
polypeptides
Prior art date
Application number
ECSENADI20232960A
Other languages
English (en)
Inventor
Judy Paterson
Isabelle Sermadiras
Esther Martin
Peng Ke
Monika Papworth
Original Assignee
Medimmune Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medimmune Ltd filed Critical Medimmune Ltd
Publication of ECSP23002960A publication Critical patent/ECSP23002960A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/64—Relaxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2221—Relaxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Cardiology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Hospice & Palliative Care (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención se refiere a polipéptidos de fusión heterodiméricos de Relaxina, en particular, a polipéptidos de fusión heterodiméricos de Relaxina 2 y a usos de los mismos. Por tanto, la invención proporciona polipéptidos de fusión de Relaxina, moléculas de ácido nucleico, vectores, células hospedadoras, composiciones farmacéuticas y kits que comprenden los mismos y usos de los mismos, incluyendo métodos de tratamiento. Los polipéptidos y las composiciones de la invención pueden ser útiles, en particular, en el tratamiento de enfermedades cardiovasculares, por ejemplo, para el tratamiento de la insuficiencia cardíaca.
ECSENADI20232960A 2020-06-17 2023-01-16 Fusiones heterodiméricas de relaxina y usos de las mismas ECSP23002960A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202063040250P 2020-06-17 2020-06-17

Publications (1)

Publication Number Publication Date
ECSP23002960A true ECSP23002960A (es) 2023-03-31

Family

ID=76584509

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI20232960A ECSP23002960A (es) 2020-06-17 2023-01-16 Fusiones heterodiméricas de relaxina y usos de las mismas

Country Status (17)

Country Link
US (2) US11795205B2 (es)
EP (1) EP4168434A1 (es)
JP (1) JP2023530335A (es)
KR (1) KR20230024994A (es)
CN (1) CN115916813A (es)
AR (1) AR125007A1 (es)
AU (2) AU2021290997C1 (es)
BR (1) BR112022025019A2 (es)
CA (1) CA3186143A1 (es)
CL (1) CL2022003578A1 (es)
CO (1) CO2023000038A2 (es)
CR (1) CR20230015A (es)
EC (1) ECSP23002960A (es)
IL (1) IL298786A (es)
MX (1) MX2022016340A (es)
TW (1) TW202214673A (es)
WO (1) WO2021255127A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024015634A2 (en) * 2022-07-15 2024-01-18 Nutcracker Therapeutics, Inc. Mrna therapies including sirp-alpha
WO2024121362A1 (en) 2022-12-09 2024-06-13 Astrazeneca Ab Dosing regimens using heterodimeric relaxin fusions
WO2024184206A1 (en) 2023-03-03 2024-09-12 Astrazeneca Ab Pharmaceutical formulation comprising heterodimeric relaxin fusion proteins and uses thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1355919B1 (en) 2000-12-12 2010-11-24 MedImmune, LLC Molecules with extended half-lives, compositions and uses thereof
US8389475B2 (en) * 2009-08-10 2013-03-05 The Board Of Trustees Of The Leland Stanford Junior University Relaxin analogs
AU2011325833C1 (en) * 2010-11-05 2017-07-13 Zymeworks Bc Inc. Stable heterodimeric antibody design with mutations in the Fc domain
KR20140054009A (ko) * 2011-07-01 2014-05-08 바이엘 인텔렉쳐 프로퍼티 게엠베하 릴랙신 융합 폴리펩타이드 및 그의 용도
AR094147A1 (es) 2012-12-27 2015-07-15 Bayer Pharma Aktiengellschaft Polipeptidos de fusion con actividad de relaxina y sus usos
EP3107938B1 (en) * 2014-05-28 2022-05-04 Zymeworks Inc. Modified antigen binding polypeptide constructs and uses thereof
JP2020505029A (ja) * 2017-01-25 2020-02-20 メディミューン，エルエルシー リラキシン融合ポリペプチドおよびその使用

Also Published As

Publication number Publication date
KR20230024994A (ko) 2023-02-21
BR112022025019A2 (pt) 2022-12-27
US20220017591A1 (en) 2022-01-20
MX2022016340A (es) 2023-01-24
TW202214673A (zh) 2022-04-16
CL2022003578A1 (es) 2023-06-09
AU2021290997C1 (en) 2024-01-04
JP2023530335A (ja) 2023-07-14
CN115916813A (zh) 2023-04-04
IL298786A (en) 2023-02-01
AU2021290997B2 (en) 2023-10-12
US11795205B2 (en) 2023-10-24
WO2021255127A1 (en) 2021-12-23
AR125007A1 (es) 2023-05-31
CA3186143A1 (en) 2021-12-23
CO2023000038A2 (es) 2023-01-16
AU2021290997A1 (en) 2023-02-09
AU2024200074A1 (en) 2024-01-25
CR20230015A (es) 2023-02-17
US20240025958A1 (en) 2024-01-25
EP4168434A1 (en) 2023-04-26

Similar Documents

Publication Publication Date Title
ECSP23002960A (es) Fusiones heterodiméricas de relaxina y usos de las mismas
BR112021005769A2 (pt) proteínas de ligação a dll3 e métodos de uso
CL2018000537A1 (es) Anticuerpo anti-factor d del complemento; polinucleótido codificante; vector que comprende dicho polinucleótido; célula húesped que comprende dicho vector; método de fabricación de anticuerpo; composición farmacéutica que lo comprende; uso del anticuerpo para tratar trastornos inflamatorios o trastornos oculares (divisional de cl 1001-2009).
PE20161324A1 (es) Proteinas de fusion de interleucina-2 y usos de las mismas
BR112022027096A2 (pt) Composições e métodos relacionados a agentes terapêuticos ativáveis
BR112022016550A2 (pt) Proteínas de ligação a flt3 e métodos de uso
BR112012006501A8 (pt) Polipeptídios e usos dos mesmos
AR030236A1 (es) Moléculas similares a il-17 y usos de las mismas
BR112022013236A2 (pt) Anticorpos anti-cd73 e usos dos mesmos
BR112018067597A8 (pt) célula progenitora de fígado adulto, população celular, material biológico, composição, método para avaliar a eficácia, o metabolismo, a estabilidade e/ou a toxicidade de um ou mais compostos, uso da célula ou população celular e kit
BR112018067946A2 (pt) formulações tópicas contendo ciclosporina e usos das mesmas
CO2020000369A2 (es) Polipéptidos que se unen al componente del complemento c5 o albumina sérica y proteínas de fusión de los mismos
AR013528A1 (es) PROTEíNA-2 QUIMIOTÁCTICA MONOCíTICA (MCP-2) HUMANA AMINO TERMINALMENTE TRUNCADA, MOLÉCULA DE ADN QUE LA CODIFICA, VECTOR DE EXPRESIoN Y CÉLULA HUÉSPED CORRESPONDIENTES, PROCESO RECOMBINANTE PARA PREPARAR DICHAS PROTEíNAS, USO DE DICHAS PROTEíNAS PARA LA FABRICACIoN DE UN MEDICAMENTO uTIL PARA LA TER
Burns et al. Pannexin protein expression in the rat middle cerebral artery
CO2021005083A2 (es) Distrofinas miniaturizadas y usos de las mismas
AR030554A1 (es) Moleculas similares a receptores il-17 y usos de las mismas
PE20190375A1 (es) Inhibidor de esterasa c1 conjugado y sus usos
AR051928A1 (es) Peptidos y derivados tipo apl de la hsp60 y composiciones farmaceuticas
CO2024010639A2 (es) Inserción de anti-tfr:gaa y anti-cd63:gaa para el tratamiento de la enfermedad de pompe
PE20050197A1 (es) Anticuerpos de virus anti-dengue, composiciones, metodos y usos
BR112022008201A2 (pt) Degradação de proteínas de superfície usando agente de ligação biespecífico
Lester Self-construal and the fear of death
BR112021019139A2 (pt) Célula de mamífero manipulada, composição, molécula isolada de dna de fita dupla, dispositivo implantável, cápsula de hidrogel, e, método de tratamento de um paciente com doença de fabry
CL2023002285A1 (es) Fracciones que prolongan la semivida y métodos de uso de estas
BR112022027124A2 (pt) Formulações para promover a hidratação e métodos de uso das mesmas